Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Convenience Claims Can Put Companies On Slippery Promotional Ground

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA cites an ad for Sanofi-Aventis' prostate cancer therapy Eligard for implying better patient quality of life and more physician efficiency because of less-frequent injections.
Advertisement

Related Content

Convenience Claims, Squinty Risk Info For Arbor's Nitro Spray Draw FDA Letter
Convenience Claims, Squinty Risk Info For Arbor's Nitro Spray Draw FDA Letter
Superiority Claims Based On Drug Delivery System Fail DDMAC Test
Superiority Claims Based On Drug Delivery System Fail DDMAC Test
DDMAC Goes After Clinical Trial Evidence Again
DDMAC Goes After Clinical Trial Evidence Again

Topics

Advertisement
UsernamePublicRestriction

Register

PS070551

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel